Article Type
Changed
Mon, 11/04/2019 - 14:52
Display Headline
Assessing First-Line Treatment of Pediatric Migraine
Cephalalgia; ePub 2019 Feb 20; Seng, Gelfand, et al.

Demographics and migraine diagnosis in the pediatric population are associated with evidence-based medicine and opioid/barbiturates. This according to a recent study that aimed to evaluate providers’ use and predictors of evidence-based medicine or opioid/barbiturate as first-line acute treatment for children’s initial presentation of acute migraine or primary headache. Primary care, therefore, provides an opportunity to target provider interventions to enhance effective pediatric headache treatment. This retrospective, observational study utilized patient (children aged 6–17) and provider/encounter characteristics extracted from the patient’s electronic health record from 2008 to 2014 during an initial encounter for migraine or primary headache. Researchers found:

  • In all, 38,926 patients (56.7% female, mean age=12.1) and 1617 providers were evaluated.
  • Only 17.7% of patients were diagnosed with migraine; 16.1% received evidence-based medicine.
  • Older children (OR=1.07), females (OR=1.14), and those diagnosed with migraine (OR=4.71) were more likely to receive evidence-based medicine.
  • Among prescriptions, 15.8% were for opioids/barbiturates.
  • Older children (OR=1.14) and those cared for in the emergency department/urgent care (OR=2.02) were at increased risk.

 

 

Seng EK, Gelfand AA, Nicholson RA. Assessing evidence-based medicine and opioid/barbiturate as first-line acute treatment of pediatric migraine and primary headache: A retrospective observational study of health systems data. [Published online ahead of print February 20, 2019]. Cephalalgia. doi:10.1177%2F0333102419833080.

Publications
Topics
Sections
Cephalalgia; ePub 2019 Feb 20; Seng, Gelfand, et al.
Cephalalgia; ePub 2019 Feb 20; Seng, Gelfand, et al.

Demographics and migraine diagnosis in the pediatric population are associated with evidence-based medicine and opioid/barbiturates. This according to a recent study that aimed to evaluate providers’ use and predictors of evidence-based medicine or opioid/barbiturate as first-line acute treatment for children’s initial presentation of acute migraine or primary headache. Primary care, therefore, provides an opportunity to target provider interventions to enhance effective pediatric headache treatment. This retrospective, observational study utilized patient (children aged 6–17) and provider/encounter characteristics extracted from the patient’s electronic health record from 2008 to 2014 during an initial encounter for migraine or primary headache. Researchers found:

  • In all, 38,926 patients (56.7% female, mean age=12.1) and 1617 providers were evaluated.
  • Only 17.7% of patients were diagnosed with migraine; 16.1% received evidence-based medicine.
  • Older children (OR=1.07), females (OR=1.14), and those diagnosed with migraine (OR=4.71) were more likely to receive evidence-based medicine.
  • Among prescriptions, 15.8% were for opioids/barbiturates.
  • Older children (OR=1.14) and those cared for in the emergency department/urgent care (OR=2.02) were at increased risk.

 

 

Seng EK, Gelfand AA, Nicholson RA. Assessing evidence-based medicine and opioid/barbiturate as first-line acute treatment of pediatric migraine and primary headache: A retrospective observational study of health systems data. [Published online ahead of print February 20, 2019]. Cephalalgia. doi:10.1177%2F0333102419833080.

Demographics and migraine diagnosis in the pediatric population are associated with evidence-based medicine and opioid/barbiturates. This according to a recent study that aimed to evaluate providers’ use and predictors of evidence-based medicine or opioid/barbiturate as first-line acute treatment for children’s initial presentation of acute migraine or primary headache. Primary care, therefore, provides an opportunity to target provider interventions to enhance effective pediatric headache treatment. This retrospective, observational study utilized patient (children aged 6–17) and provider/encounter characteristics extracted from the patient’s electronic health record from 2008 to 2014 during an initial encounter for migraine or primary headache. Researchers found:

  • In all, 38,926 patients (56.7% female, mean age=12.1) and 1617 providers were evaluated.
  • Only 17.7% of patients were diagnosed with migraine; 16.1% received evidence-based medicine.
  • Older children (OR=1.07), females (OR=1.14), and those diagnosed with migraine (OR=4.71) were more likely to receive evidence-based medicine.
  • Among prescriptions, 15.8% were for opioids/barbiturates.
  • Older children (OR=1.14) and those cared for in the emergency department/urgent care (OR=2.02) were at increased risk.

 

 

Seng EK, Gelfand AA, Nicholson RA. Assessing evidence-based medicine and opioid/barbiturate as first-line acute treatment of pediatric migraine and primary headache: A retrospective observational study of health systems data. [Published online ahead of print February 20, 2019]. Cephalalgia. doi:10.1177%2F0333102419833080.

Publications
Publications
Topics
Article Type
Display Headline
Assessing First-Line Treatment of Pediatric Migraine
Display Headline
Assessing First-Line Treatment of Pediatric Migraine
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Fri, 03/01/2019 - 10:15
Un-Gate On Date
Fri, 03/01/2019 - 10:15
Use ProPublica
CFC Schedule Remove Status
Fri, 03/01/2019 - 10:15
Hide sidebar & use full width
render the right sidebar.